Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 52,183 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 52,183 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total transaction of $933,553.87. Following the sale, the chief financial officer now owns 225,571 shares of the company’s stock, valued at approximately $4,035,465.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Day One Biopharmaceuticals Trading Down 2.3 %

NASDAQ DAWN opened at $17.17 on Friday. The company’s 50 day simple moving average is $15.41 and its two-hundred day simple moving average is $13.98. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, research analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on DAWN. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Needham & Company LLC upped their price target on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Piper Sandler reiterated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of DAWN. First Turn Management LLC bought a new position in Day One Biopharmaceuticals in the fourth quarter valued at $24,834,000. TimesSquare Capital Management LLC lifted its position in Day One Biopharmaceuticals by 45.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 1,666,065 shares of the company’s stock worth $24,325,000 after buying an additional 523,455 shares during the last quarter. Braidwell LP boosted its stake in Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after buying an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the last quarter. Finally, Superstring Capital Management LP purchased a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth approximately $5,543,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.